Literature DB >> 10076567

Growth inhibition of A549 human lung adenocarcinoma cells by L-canavanine is associated with p21/WAF1 induction.

Y Ding1, Y Matsukawa, N OhtaniFujita, D Kato, S Dao, T Fujii, Y Naito, T Yoshikawa, T Sakai, G A Rosenthal.   

Abstract

L-Canavanine (CAV) is a higher plant nonprotein amino acid and a potent L-arginine antimetabolite. CAV can inhibit the proliferation of tumor cells in vitro and in vivo, but little is known regarding the molecular mechanisms mediating these effects. We demonstrated that the treatment of human lung adenocarcinoma A549 cells with CAV caused growth inhibition; G1 phase arrest is accompanied by accumulation of an incompletely phosphorylated form of the retinoblastoma protein, whose phosphorylation is necessary for cell cycle progression from G1 to S phase. In addition, CAV induces the expression of p53 and subsequent expression of a cyclin-dependent kinase inhibitor, p21/WAF1. The p53-dependent induction of p21/WAF1 and the following dephosphorylation of the retinoblastoma protein by CAV could account for the observed CAV-mediated G1 phase arrest.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076567      PMCID: PMC5925972          DOI: 10.1111/j.1349-7006.1999.tb00667.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  29 in total

1.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  Proinsulin modified by analogues of arginine and lysine is degraded rapidly in pancreatic B-cells.

Authors:  P A Halban; M Amherdt; L Orci; A E Renold
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

4.  The effect of canavanine on protein synthesis and protein degradation in IMR-90 fibroblasts.

Authors:  D Fong; B Poole
Journal:  Biochim Biophys Acta       Date:  1982-02-26

5.  Stress response, survival and enhancement of heat sensitivity in a human melanoma cell line treated with L-canavanine.

Authors:  E Mattei; D Damasi; A M Mileo; A Delpino; U Ferrini
Journal:  Anticancer Res       Date:  1992 May-Jun       Impact factor: 2.480

6.  Enhancement of human tumor cell killing by L-canavanine in combination with gamma-radiation.

Authors:  M H Green; J F Ward
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

7.  Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies.

Authors:  D S Swaffar; C Y Ang; P B Desai; G A Rosenthal; D A Thomas; P A Crooks; W J John
Journal:  Anticancer Drugs       Date:  1995-08       Impact factor: 2.248

8.  Degradation of abnormal proteins in HeLa cells.

Authors:  W F Prouty
Journal:  J Cell Physiol       Date:  1976-07       Impact factor: 6.384

9.  Studies of L-canavanine incorporation into insectan lysozyme.

Authors:  G A Rosenthal; D L Dahlman
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

10.  L-Canavanine and protein synthesis in the tobacco hornworm Manduca sexta.

Authors:  G A Rosenthal; D L Dahlman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

View more
  2 in total

1.  L-Canavanine as a radiosensitization agent for human pancreatic cancer cells.

Authors:  Aimee K Bence; Val R Adams; Peter A Crooks
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

2.  Integrated multi-omic data reveal the potential molecular mechanisms of the nutrition and flavor in Liancheng white duck meat.

Authors:  Hao Zhou; Yu Yang; Lixia Wang; Shengqiang Ye; Jiajia Liu; Ping Gong; Yunguo Qian; Huijun Zeng; Xing Chen
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.